Endotrophin & PRO-C6: The Webinar

Your details

I register for the webinar. (Participant names are not shared with other viewers.)

The Extracellular Matrix Pharmacology Congress and its industry partner, Nordic Bioscience ApS, can contact me by email with news on research, events, products, and similar. I can always withdraw my consent at any time.

Date and time

Monday

November

16:00 CET

Confirm sign-up

Endotrophin & PRO-C6: Collagen VI Biomarkers for Mechanism, Prognosis, and Drug Development

Type VI collagen sits at the intersection of fibroblast activation, fibrogenesis, and wound healing. Two assays quantify distinct aspects of this axis:

NordicPRO-C6™ measures total type VI collagen formation via the α3 chain, which contains 12 von Willebrand factor (vWF) binding domains—more than any known protein. These domains can bind and activate platelets independently of vWF, releasing TGF-β and PDGF and linking platelet biology to fibroblast activation, fibrosis, and wound repair.

NordicEndotrophin™ isolates Endotrophin, a 77-aa hormone released during type VI collagen synthesis. Endotrophin lacks vWF-binding domains but directly drives fibroblast activation and fibrogenesis. It represents the biologically active subpopulation within the broader pool of collagen VI formation fragments.

Together, these assays provide complementary insights: PRO-C6 reflects total collagen VI formation, while Endotrophin isolates the signaling activity of Endotrophin, offering a more nuanced understanding of fibrotic processes. This pairing enables diagnostic, prognostic, and pharmacodynamic readouts and supports regulated deployment on diagnostic platforms.

Learn more 

Format
60-70 minutes presentation followed by 20-30 minutes of audience Q&A.

Agenda
1. Introduction: ECM and biomarker nomenclature
- Short orientation to ECM remodeling and serological readouts.
- Where collagen-derived neo-epitopes fit in MoA, enrichment, and PD.

2. Endotrophin: a collagen-derived hormone
- Molecular origin during collagen VI synthesis (77-aa release).
- Direct effects on fibroblasts; initiation of wound-healing/fibrogenic programs.

3. Understanding type VI collagen
- Architecture and α3 chain features; 12 vWF-binding domains and platelet activation; TGF-β/PDGF release.
- Why collagen VI is central across fibrotic pathologies.

4. Assay spotlight: NordicPRO-C6™ vs. NordicEndotrophin™
- PRO-C6: total type VI collagen formation/pool.
- Endotrophin: selective quantification of the active signaling hormone.
- Complementarity for mechanism + outcome.

5. Clinical translation
- Endotrophin as outcome biomarker in CVD, kidney, skin, lung, and fibrostenosis.
- Weight-dependent and weight-independent modulation of fibroblast activity and Endotrophin/PRO-C6 levels.
- Type VI collagen biomarkers: tissue formation vs. tissue degradation signatures and links to disease trajectories.

6. GWAS and Mendelian randomization
- Connecting Endotrophin to cardiovascular outcomes.
- Integration with serological measures.

7. From discovery to development
- Diagnostic, prognostic, and pharmacodynamic roles (“unicorn biomarkers”).
- Regulatory interactions and technical excellence on diagnostic platforms; implementation in multicenter studies.

8. Q&A
- Open discussion with Dr. Morten Karsdal and Dr. Federica Genovese


Speakers
Prof. Dr. Morten Karsdal and Dr. Federica Genovese

Expected duration
90 minutes

Share this webinar